Chai Young Jun, Suh Hyunsuk, Woo Jung-Woo, Yu Hyeong Won, Song Ra-Yeong, Kwon Hyungju, Lee Kyu Eun
Department of Surgery, Seoul National University Boramae Medical Center, 20 Boramae-ro 5-gil, Dongjak-gu, Seoul, 156-70, Korea.
Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 110-744, Korea.
Surg Endosc. 2017 Mar;31(3):1235-1240. doi: 10.1007/s00464-016-5097-1. Epub 2016 Jul 15.
The safety of robotic thyroidectomy (RT) for small-sized thyroid carcinomas has been well established. The surgical outcomes of bilateral axillo-breast approach RT for thyroid carcinomas larger than 2 cm were evaluated and compared with those of open thyroidectomy (OT).
The medical records of patients who underwent total thyroidectomy or hemithyroidectomy followed by completion thyroidectomy for differentiated thyroid carcinomas measuring 2-4 cm were retrospectively reviewed.
The study included 86 patients who underwent RT (n = 21) or OT (n = 65) with mean ages of 30.8 and 51.6 years, respectively. The mean tumor size was 2.8 cm in both groups. There were no significant differences between the RT and OT groups in vocal cord palsy rate (transient, 19.0 vs. 9.2 %; permanent, 0 vs. 1.5 %), postoperative hypoparathyroidism rate (transient, 19.0 vs. 33.8 %; permanent, 4.8 vs. 1.5 %), and the number of retrieved central lymph nodes in papillary thyroid carcinoma patients (6.4 ± 3.5 vs. 6.1 ± 3.9, respectively). The proportion of the patients with serum stimulated thyroglobulin level of <1.0 ng/ml at the initial radioactive iodine treatment was 64.7 % (11/17) for RT group and 66.0 % (35/53) for OT group (p = 0.920). There were three patients (1 RT and 2 OT) who had a biochemical incomplete response, and there was no case of anatomical recurrence or mortality during the median follow-up period of 40.2 months.
RT is a safe and oncologically sound treatment option for differentiated thyroid carcinomas measuring 2-4 cm in a selected group of patients. The role of RT should be evaluated in correlation with technological advances and increased experience.
机器人甲状腺切除术(RT)治疗小尺寸甲状腺癌的安全性已得到充分证实。本研究评估了双侧腋窝-乳房入路RT治疗直径大于2 cm的甲状腺癌的手术效果,并与开放甲状腺切除术(OT)的效果进行比较。
回顾性分析接受全甲状腺切除术或半甲状腺切除术,随后对直径2-4 cm的分化型甲状腺癌行甲状腺全切术患者的病历资料。
该研究纳入86例分别接受RT(n = 21)或OT(n = 65)的患者,平均年龄分别为30.8岁和51.6岁。两组患者的平均肿瘤大小均为2.8 cm。RT组和OT组在声带麻痹发生率(暂时性,19.0% 对9.2%;永久性,0对1.5%)、术后甲状旁腺功能减退发生率(暂时性,19.0% 对33.8%;永久性,4.8% 对1.5%)以及甲状腺乳头状癌患者中央区淋巴结清扫数量(分别为6.4 ± 3.5和6.1 ± 3.9)方面均无显著差异。初始放射性碘治疗时血清刺激甲状腺球蛋白水平<1.0 ng/ml的患者比例,RT组为64.7%(11/17),OT组为66.0%(35/53)(p = 0.920)。有3例患者(1例RT和2例OT)出现生化不完全缓解,在40.2个月的中位随访期内无解剖学复发或死亡病例。
对于特定组中直径2-4 cm的分化型甲状腺癌患者,RT是一种安全且肿瘤学效果良好的治疗选择。应结合技术进步和经验增加来评估RT的作用。